Pfizer Buys Biohaven For $11.6 Billion Betting On CGRP Meds
Pfizer is putting its substantial gain from COVID-19 drugs to good use by making deals. The company has decided it wants more, six months...
Early COVID-19 Cases Still Suffering Lingering Symptoms
As per a new study that may be one of the oldest and largest on record to track people with protracted COVID, the vast...
Boosters For COVID-19 Considerably Vital Than In The Past
The Biden administration estimates that up to 100 million additional individuals could contract COVID-19 in the fall and winter due to diminishing immunity and...
In DELIVER Phase III Study, Farxiga Achieved Primary Outcome
DELIVER is the world's largest study of heart failure with intact ejection fraction. The DELIVER phase 3 trial produced favourable findings for AstraZeneca. It...
Sanofi Drug Components Venture Comes To Life After Two Years
It's a fact: EUROAPI debuted on the Euronext exchange two years and one pandemic after Sanofi announced plans to sell off its European pharma...
Quality Issues Lead To Novartis Halting Cancer Radiotherapy
Novartis has halted production of its two commercial radioligand treatments for cancer care just weeks after the FDA approved them.
Novartis confirmed on May 5th...
FDA Regulates Use of J&J COVID Jab Due To Risk Of Thrombosis
The US Food and Drug Administration recently announced that the Johnson & Johnson/Janssen COVID-19 vaccine's urgent use permit will be restricted to people 18...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...